Britannia Life Sciences Inc.
BLAB
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -- | 40.21% | -- | -- | 88.83% |
| Total Depreciation and Amortization | -- | 1.77% | -- | -- | -0.91% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -309.29% | -- | -- | -52.08% |
| Change in Net Operating Assets | -- | 100.59% | -- | -- | 58.61% |
| Cash from Operations | -- | 54.08% | -- | -- | 703.03% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -1,908.97% | -- | -- | -7.28% |
| Cash from Investing | -- | -1,908.97% | -- | -- | -7.28% |
| Total Debt Issued | -- | -- | -- | -- | -106.42% |
| Total Debt Repaid | -- | -1.68% | -- | -- | 2.98% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 0.58% |
| Cash from Financing | -- | -1.85% | -- | -- | -414.83% |
| Foreign Exchange rate Adjustments | -- | 179.07% | -- | -- | -103.30% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -288.37% | -- | -- | -94.54% |